Homocysteine and Myocardial Injury

J David Spence^{1

2}

Affiliations

¹ Neurology & Clinical Pharmacology Divisions, Western University, London, Ontario, Canada.
² Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada.

Editorial

J David Spence. JACC Asia. 2024.

. 2024 Aug 6;4(8):621-623.

doi: 10.1016/j.jacasi.2024.06.003. eCollection 2024 Aug.

J David Spence^{1

2}

¹ Neurology & Clinical Pharmacology Divisions, Western University, London, Ontario, Canada.
² Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada.

No abstract available

Keywords: cardiac biomarker; folate; homocysteine; subclinical myocardial injury; vitamin B12.

Conflict of interest statement

The author has reported that he has no relationships relevant to the contents of this paper to disclose.

1. Tan X., Tang F., Tian W., et al. Homocysteine metabolism, subclinical myocardial injury, and cardiovascular mortality in the general population. JACC Asia. 2024;4(8):609–620.
1. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149–1155. - PubMed
1. Nygård O., Nordehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236. - PubMed
1. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–575. - PubMed
1. Spence J.D., Bang H., Chambless L.E., Stampfer M.J. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke. 2005;36(11):2404–2409. - PubMed